A Phase 2 Study of the JAK1/JA2 Inhibitor Ruxolitinib with Chemotherapy in Children with De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia
|Effective start/end date||7/1/16 → 1/31/24|
- THE CHILDREN'S HOSPITAL OF PHILADELPHIA
- INCYTE CORPORATION
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.